- Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapies.
Oncol Res Treat. 2026 Feb 16:1-13. doi: 10.1159/000551018. Epub ahead of print.
Weide R, Mohm J, Gärtner M, Fuxius S, Vehling-Kaiser U, Forstbauer H, Lipke J, Rothe A, Verpoort K, Feiten S. - Real-world progression-free survival and overall survival in patients with HR+/HER2- advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.
Int J Cancer. 2026 Mar 6. doi: 10.1002/ijc.70397. Epub ahead of print.
Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A. - Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
Leukemia. 2026 Feb;40(2):410-417. doi: 10.1038/s41375-025-02859-1. Epub 2026 Jan 12.
Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke G-N, Lang F, Krause SW, Möhle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuß A, Göthert JR, Ernst T, Abu-Samra M, Höffkes H-G, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C.
- Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.Blood. 2025 Sep 4:blood.2025028550. doi: 10.1182/blood.2025028550. Epub ahead of print. PMID: 40906922.
Simon F, Ligtvoet R, Bohn JP, Nösslinger T, von Tresckow J, Liersch R, Gaska T, Jentsch-Ulrich K, Gärtner M, Wolff T, Schwaner I, Wolf D, Schneider C, Vehling-Kaiser U, Ritgen M, Spoer C, Eckart MJ, Decker T, Chakupurakal G, Schöttker B, Kisro J, Kreuzer KA, Tausch E, Stilgenbauer S, Robrecht S, Stumpf J, Fink A, Fürstenau M, Fischer K, Goede V, Hallek MJ, Eichhorst BF. - Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study.ESMO Open (2025), 10 (6).
Decker T, Brucker C, Engel A, Fasching PA, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Roos C, Wilhelm N, Wöckel A. - Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care.Cancers (2024),16,1255.
Weide R, Feiten S, Waßmann C, Rendenbach B, Braun U, Burkhard O, Ehscheidt P, Schmidt M. - Age and Performance Status Significantly Influence Outcome despite the Advent of New Therapy Options in Multiple Myeloma.Cancer Sci Res (2024);7(2):1-6.
Chakupurakal G, Feiten S, Schnell R, Steinmetz TH, Müller L, Burkhard O, Braun U, Ehscheidt P, Tamm I, Rendenbach B, Weide R. - Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic.BMC Immunol (2023) 24,2.
Lutz C, Feiten S, Chakupurakal G, Heymanns J, Thomalla J, van Roye C, Weide R. - Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.Cochrane Database Syst Rev (2023);6(6):CD009159. doi:10.1002/14651858.CD009159.pub3
Chakupurakal G, Freudenberger P, Skoetz N, Ahr H, Theurich S. - Association between serum IgG concentrations and the incidence of infections in patients with chronic lymphocytic leukemia and secondary immunodeficiency under treatment with Privigen.Int J Clin Pharmacol Ther (2024); 62: 241-249. DOI 10.5414/CP204473
Otremba B, Haslbauer F, Reiser M, Weide R, Obermeier M, Pfründer D. - Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.Ann Hematol (2024);103(5):1569-1575. doi: 10.1007/s00277-024-05702-2.
Franke GN, Loewe G, Reiser M, Linde H, Josting A, von der Heyde E, Platzbecker U, Weide R, Tesch H, Nusch A, Dengler J, Jentsch-Ullrich K. - Evolutionary trajectories of small cell lung cancer under therapy.Nature (2024);627(8005):880-889. doi: 10.1038/s41586-024-07177-7.
George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, Jürgens J, Stoelben E, Brockmann M, Grau S, Sebastian M, Stratmann JA, Kern J, Hummel HD, Hegedüs B, Schuler M, Plönes T, Aigner C, Elter T, Toepelt K, Ko YD, Kurz S, Grohé C, Serke M, Höpker K, Hagmeyer L, Doerr F, Hekmath K, Strapatsas J, Kambartel KO, Chakupurakal G, Busch A, Bauernfeind FG, Griesinger F, Luers A, Dirks W, Wiewrodt R, Luecke A, Rodermann E, Diel A, Hagen V, Severin K, Ullrich RT, Reinhardt HC, Quaas A, Bogus M, Courts C, Nürnberg P, Becker K, Achter V, Büttner R, Wolf J, Peifer M, Thomas RK. - Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.Oncologist (2023);28(12):e1152-e1159. doi: 10.1093/oncolo/oyad191.
Lück HJ, Schmidt M, Hesse T, Hoffmann O, Heinrich BJ, Park-Simon TW, Grischke EM, Weide R, Müller-Huesmann H, Lüdtke-Heckenkamp K, Fischer D, Zemlin C, Kögel M, Wu J, Schmitz H, Engelbrecht C, Jackisch C. - Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.Eur Urol Open Sci (2023);53:31-37. doi: 10.1016/j.euros.2023.04.018.
Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, Kingreen D, Klümper N, Ivanyi P, von Amsberg G, Heers H, Roghmann F, Tauber RL, Cathomas R, Hofer L, Niegisch G, Klee M, Ehrenberg R, Hassler A, Hadaschik BA, Grünwald V, Darr C. - Ansprache sensibler Themen im ärztlichen Gespräch mit übersetzenden Angehörigen bei der Identifikation psycho-onkologischer Versorgungsbedarfe von Patient*innen mit Migrationshintergrund.Forum (2022), 37:289–293.
Hermes-Moll K, Hempler I, Riccetti N, Chakupurakal G, Fried M, Knorrenschild JR, Köhler A, Mosthaf FA, Pelz H, Schmitz S, Heidt V, Singer S. - Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.The Lancet Haematology 2022, 9(11):e810-e821.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC, for the German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. - Curricular course for medical students at a hematology and oncology specialty practice, 2010-2022.GMS J Med Educ. 2022;39(4):Doc40. DOI: 10.3205/zma001561, URN: urn:nbn:de:0183-zma0015619
Weide R, Thomalla J, van Roye C, Chakupurakal G, Heymanns J, Köppler H, Feiten S, Nickel JA, Schmidberger H, Theobald M, Lutz C. - Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2113693
Geßner C, Fietz T, Losem C, Lück A, Schulz H, Niemeier B, Groschek M, Eschenburg H, Weide R, Kretzschmar A, Frost N, Hipp J, Harde J, Matillon CD, Grebhardt S, Potthoff K. - Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.Ann Oncol (2022); S0923-7534(22)03791-7. doi: 10.1016/j.annonc.2022.07.1940
Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J-U, Furlanetto J, Zahm D-M, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching P A, Nekljudova V, Denkert C, Untch M, GBG and AGO-B. - Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
ESMO Open (2022); 7(3):100495. doi: 10.1016/j.esmoop.2022.100495
Laakmann E, Witzel I, Neunhöffer T, Park-Simon T-W, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill N, Zahm D-M, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. - Shared decision-making in routine breast cancer care in Germany—A cross-sectional study.
Psychooncology (2022); 1‐7.
Feiten S, Scholl I, Dünnebacke J, Schmidt M, Franzen A, Ernst W, Spaderna H, Weide R. - Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores Cancers 2021, 13(4), 844;
Riecke K, Müller V, Weide R, Schmidt M, Park-Simon T-W, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Laakmann E, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I - Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases.
Cancers (2020); 12(10): 2787. doi: 10.3390/cancers12102787.
Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching PA, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. - Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement
BMC Immun (2020) 21:39. K
Weide R , Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn M-O, Wierecky J, Braun U, Hensel M, Klausmann M, Fleckenstein D, Ehscheidt P, Feiten S - Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Hemasphere (2020); 4(1): e336. doi: 10.1097/HS9.0000000000000336.
Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst B.
-
Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors. J Oncol Pharm Pract (2020). doi: 10.1177/1078155220946381 [Online ahead of print].
Rosentreter J, Alt J, Fried M, Chakupurakal G, Stratmann J, Krämer I. - DNVF Memorandum Versorgungsforschung in der Onkologie.
Das Gesundheitswesen (2020). doi: 10.1055/a-1191-3759.
Kowalski C, Albert U-S, Baumann W, Carl G, Ernstmann N, Hermes-Moll K, Fallenberg E A, Feick G, Feiten S, Härter M, Heidt V, Heuser C, Hübner J, Joos S, Katalinic A, Kempkens Ö, Kerek-Bodden H, Klinkhammer-Schalke M, Koller M, Langer T, Lehner B, Lux M P, Maatouk I, Pfaff H, Ratsch B, Schach S, Scholl I, Skoetz N, Voltz R, Wiskemann J, Inwald E C. - Infektionskontrolle bei hämatologischen und onkologischen Neoplasien.
TumorDiagn u Ther (2020); 41: 299-301. https://doi.org/10.1055/a-1132-1156.
Weide R - Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017.
Leuk Lymphoma (2019); 61(3): 557-566. https://doi.org/10.1080/10428194.2019.1680840.
Weide R, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, Köppler H, Lutschkin J, van Roye C, Thomalla J, Heymanns J. - Response to the letter to the Editor concerning our article ‚High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany‘
Support Care Cancer (2019).
Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, Hensel M, Hansen R, Weide R. - Treatment and Outcome of Patients with Palliative Non-small Cell Lung Cancer (NSCLC) in Routine Outpatient Care Over Two Decades.
J Cancer Sci Ther/Vol.11.5 167(2019), Vol 11(5)
Chakupurakal G, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Lutschkin J, Thomalla J, van Roye C, Weide R. - Entfernungen überbrücken – Telemedizin.
In: Jünger J. (Hrsg.) 2018. Ärztliche Kommunikation: Praxisbuch zum Masterplan Medizinstudium 2020, Stuttgart: Schattauer, S. 570 – 575.
Vitinius F, Rarek M, Peltzer S, Heymanns J. - High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany. Support Care Cancer (2019), 27:4265–4271. doi: 10.1007/s00520-019-04721-4
Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, Hensel M, Hansen R, Weide R. - Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019;106:181-192.
Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S - Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2018 Dec 4. pii: haematol.2018.206797. doi: 10.3324/haematol.2018.206797. [Epub ahead of print]
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M. - Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer. 2018;102:1-9.
Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon TJ, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Würschmidt F, Schem C, Bechtner C, Würstlein R, Fehm T, Möbus V, Burchardi N, Loibl S, Müller V. - Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398-2406.
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. - Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA, Lawo JP, Weide R, Jochems J, Puli S, Hofmann J, Pfruender D, Rojavin MA Int Immunopharmacol 2018; 66:119-126. - Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices
Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R Oncol Res Treat 2017;40:784-788. - Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J Leukemia 2017;31(11):2398-2406. - Versorgungsforschung in onkologischen Schwerpunktpraxen in Deutschland
Weide R Der Onkologe 2017; 23:1-6 - Standard of care of patients with Chronic Myeloid Leukemia (CML) treated in community based oncology group practices between 2001-2015 in Rhineland-Palatinate (Germany)
Weide R, Rendenbach B, Grundheber M, Burkhard O, Behringer J, Maasberg M, Ehscheidt P, Strehl JW, Hansen R, Feiten S Applied Cancer Research 2017;37:26
- Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. TumorDiagn u Ther 2016;37:393-397
- Follow-up Reality for Breast Cancer Patients – Standardised Survey of Patients and Physicians and Analysis of Treatment Data
Feiten S, Dünnebacke J, Friesenhahn V, Heymanns J, Köppler H, Meister R, Thomalla J, van Roye C, Wey D, Weide R Geburtshilfe Frauenheilkd 2016; 76(05): 557-563 - Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice
Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, van Roye C, Thomalla J SpringerPlus (2016) 5:270 - Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H. Oncol Res Treat 2016;39:41-44. - Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.Dtsch Med Wochenschr 2015;140(19):e201-6
- NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis
Kurbacher C.M., Fietz T, Diel I, Egert, Hurtz H-J, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens C, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein R W Oncol Res Treat 2015;38:221–229
- Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive Tumors.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H SpringerPlus 2014 3:535. - Breast cancer morbidity – questionnaire survey of patients on the long term effects of disease and adjuvant therapy.
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R Dtsch Arztebl Int 2014; 111: 537-44. - The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison.
Herth I, Dietrich S, Benner A, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Tran TH, Weide R, Hensel M, Knauf W, Franz-Werner J, Welslau M, Procaccianti M, Görner M, Meissner J, Luft T, Schönland S, Witzens-Harig M, Zenz T, Ho AD, Dreger P Ann Oncol. 2014;25(1):200-6. - Psychosocial Distress in Caregivers of Patients with a Metastatic Solid Tumor in Routine Care: A Survey in a Community Based Oncology Group Practice in Germany.
Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Mergenthaler U, Thomalla J, van Roye C & Weide R Cancer and Clinical Oncology 2013,2(2):1-10. - Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, Mergenthaler U, van Roye C & Köppler H Cancer and Clinical Oncology 2013, Vol. 2 (1):17-27 - Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C & Köppler H Leuk Lymphoma. 2013;54(8):1640-6 - Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; GCLLSG. Br J Haematol. 2012;158(2):238-41. - Identifying Caregivers and Their Meaning for Patients with Metastatic Solid Tumours in Routine Care: A Survey at a Community-Based Oncology Group Practice in Germany
Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Mergenthaler U, Thomalla J, van Roye C & Köppler H Cancer and Clinical Oncology. 2012; 1(1): 41-51
- Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer K-A, Schlenk R, Ganser A, Hofmann W-K, Aul C, Krieger O, Kündgen A, Haas R, Hasford J and Giagounidis A Leukemia 2012: doi:10.1038/leu.2011.391 - Evaluation of psychosocial distress in patients treated in a community-based oncology group practice in Germany
Mergenthaler U, Heymanns J, Köppler H, Thomalla J, van Roye C, Schenk J, Weide R. Ann Oncol. 2011;22(4):931-8 - Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Weide R, Köppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS. J Cancer Res Ther.2010 Jan-Mar;6(1):31-5 - The impact of new treatment options for advanced colorectal cancer on routine care: Results of a retrospective analysis of 206 consecutive patients treated in a community based oncology group practice
Köppler H, Heymanns J, Thomalla J, Kleboth K, Weide R. Eur J Cancer Care 2010;19(6):795-802 Interdisziplinäre ambulante Versorgung Schmitz S, Heymanns J. Der Onkologe 2009 Oct;15:1065-1069 - Bendamustine/Mitoxantrone/Rituximab (BMR): A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia (CLL)
Weide R, Mergenthaler U, Friesenhahn V, Kleboth K, Heymanns J, Thomalla J, Köppler H. Leuk Lymphoma. 2009 Sep;50(9):1468-1474 - Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK. Clin Oncol (R Coll Radiol). 2009 Aug;21(6):448-50. Epub 2009 Feb 26. - Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, Wintfeld N, Neary M, Duh MS. Support Care Cancer. 2009 Jun;17(6):719-25. Epub 2008 Dec 17. - CT-guided percutaneous core needle biopsy in oncology outpatients: sensitivity, specificity, complications.
Steil S, Zerwas S, Moos G, Bittinger F, Hansen T, Mergenthaler U, Weide R. Onkologie. 2009 May;32(5):254-8. Epub 2009 Apr 22. - Improved survival of patients with metastatic breast cancer in routine care: results of a retrospective study in a community-based oncology group practice 1995-2005.
Weide R, Mergenthaler U, Pandorf A, Arndt H, Heymanns J, Thomalla J, Köppler H. Onkologie. 2009 Mar;32(3):107-13. Epub 2009 Feb 13. - Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice
Koeppler H, Heymanns J, Thomalla J,Kleboth K, Mergenthaler U, Weide R. Clinical Medicine: Oncology 2009:3 63-70 - Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T. Haematologica. 2009 Jan;94(1):141-4. Epub 2008 Nov 23. - Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma.
Weide R. Ther Clin Risk Manag. 2008 Aug;4(4):727-32. - Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival.
Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H. Onkologie. 2007 Dec;30(12):611-7. - High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M; German Low Grade Lymphoma Study Group. Leuk Lymphoma. 2007 Jul;48(7):1299-306.